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Abstract

Despite compelling evidence behind the efficacy of pre-exposure prophylaxis (PrEP) in
preventing human immunodeficiency virus (HIV) acquisition and its introduction in 2012, the
prescription of PrEP has remained low (Silapaswan, Krakower, & Mayer, 2016). At the Asian
and Pacific Islander Wellness Center (API), an urban primary care clinic in San Francisco,
suboptimal PrEP implementation was related to a lack of standardized practice and routine HIV
risk screening for PrEP provision. A doctorate of nursing (DNP) project was implemented to
initiate a standardized HIV risk screening protocol for identifying HIV risk and PrEP eligibility
to increase PrEP implementation at API. The impact of this protocol demonstrated an increase in
the PrEP implementation cascade, particularly in HIV risk identification, PrEP offer, and
evaluation of at-risk patients for PrEP uptake (initiation). During implementation of the HIV risk
screening protocol, however, inconsistent clinical staff compliance with the routine screening
tool led to an inadequate increase in PrEP offer for patients who tested positive for a sexually
transmitted infection (STI). This indicates a need for further reinforcement of standardized
practice and clinical staff education on the importance of combining HIV risk screening and
PrEP, with emphasis on the significant risk for HIV infection associated with positive STI, to
effectively promote patient outcomes. Implications for further research include validation of the
HIV PrEP screening tool used in the HIV risk screening protocol as a model for PrEP
implementation in the primary care setting.

Keywords: PrEP implementation, PrEP delivery, PrEP demonstration project, primary
care, pre-exposure prophylaxis, HIV prevention, HIV risk screening, PrEP screening tool,
PrEP implementation model
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Optimizing HIV PrEP Implementation in the Primary Care Setting
Introduction

In 2012, the combination antiretroviral drug, tenofovir disoproxil fumarate/emtricitabine
(TDF/FTC), was federally approved in the United States (US) for use as pre-exposure
prophylaxis (PrEP) for preventing HIV infection (Centers for Disease Control and Prevention,
2014). PrEP is the first drug of its kind to prevent HIV acquisition in high-risk populations,
proven to be up to 92% effective (CDC, 2014). While such evidence is a promising start, the lack
of widespread dissemination of the literature and practice guidelines limits its impact. Currently,
there is a need for increased implementation of the evidence, via standardized practice models, in
primary care settings providing care to at-risk populations (Silapaswan et al., 2016). The Asian
and Pacific Islander Wellness Center (API), an urban federally qualified health center (FQHC)
located in an HIV endemic area, provides care for an at-risk patient population that would benefit
from PrEP. This DNP project proposed to optimize PrEP implementation at API through
standardization of clinical practice with an emphasis on increasing routine HIV risk screening,
which can serve as a model applicable to other primary care settings.
Problem Description
Although HIV can be managed as a chronic illness in the United States for those who
have healthcare access and respond to antiretroviral treatment, it remains a serious preventable
communicable disease. In 2015, 39,513 persons were newly diagnosed with HIV in the United
States (CDC, 2016). As of June 2016, there are 16,030 people living with HIV in San Francisco
(San Francisco Department of Public Health, 2016). Because HIV is endemic in San Francisco,
an independent, volunteer-led, multi-sector consortium called the Getting to Zero San Francisco
initiative established its mission to achieve UNAIDS’s (United Nations program on HIV/AIDS)
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vision of zero new HIV infections, zero HIV deaths, and zero HIV stigma by 2020 (Getting to
Zero San Francisco, 2015) (United Nations program on HIV/AIDS, 2011).
API is a non-profit, urban primary care clinic in the Tenderloin district of San Francisco
that serves a disenfranchised patient population, consisting of lesbian, gay, bisexual, transgender
and queer (LGBTQ), and low-income people of color. As of April 2016, an estimated 61% of
patients had substantial risk for acquiring HIV due to intravenous drug use, commercial sex
work, being in an HIV serodiscordant relationship, or inconsistent safe sex practices (T. Do,
personal communication, February 25, 2016). Prior to this DNP project, API did not have an
established PrEP implementation protocol or a standardized screening process for HIV risk.
At API, the following process describes clinic workflow. Per routine, the medical
assistants (MAs) room the patient, collect vital signs, and perform routine health screenings, such
as the PHQ-2 and -9, AUDIT-C (Appendix A), and sexual history assessment. The results are
documented into the electronic health record (EHR) and reported to the nurse practitioners (NPs)
or physician before they assess the patient. Due to a lack of standardization specifying the health
screenings associated with the type of patient encounter, health screenings were performed
inconsistently. For example, the sexual history assessment was conducted for many patient
encounters but was often missed for straightforward visits, particularly STI testing. Although the
sexual history assessment screen in the EHR collected important information about sexual risk
behavior, it did not flag HIV risk. Without appropriate clinical staff training to use the sexual
history information to assess for HIV risk, the screen was ineffective for identifying at-risk
patients who qualify for PrEP.
PrEP implementation consists of the following steps, also known as a “cascade” (B.
Turner, personal communication, April 6, 2016). The first step is screening for HIV risk per
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CDC guidelines (Appendix B) (CDC, 2014). Once an at-risk patient is identified, the second step
is PrEP offer, which involves the provider discussing and offering PrEP as an HIV prevention
method. After a patient accepts PrEP offer, the third step is PrEP evaluation. Evaluation involves
laboratory testing and physical examination to confirm that a patient is eligible, in other words
safe, to start PrEP. The final step in the cascade is PrEP uptake, which is the prescription and
patient initiation of PrEP.
It is important to note that PrEP uptake can be limited by the financial cost of TDF/FTC.
The drug cost of PrEP is approximately $13,000 per patient per year (CDC, 2015). Depending on
a patient’s health insurance plan, the cost of PrEP may not be fully covered, posing a barrier to
receiving a prescription for and initiating PrEP. At API, such financial barriers to PrEP are
resolved by the PrEP case manager, now PrEP navigator, by connecting patients with the Gilead
Sciences (the pharmaceutical company that manufactures TDF/FTC) financial assistance
program and copay cards, or Medi-Cal health insurance coverage. Medi-Cal covers the entire
cost of PrEP (T. Do, personal communication, May 9, 2016).
Baseline data collected on the clinical practice of PrEP implementation at API
demonstrated that only 48% of patients with a history of sexual HIV risk, and 35% of patients at
risk for acquiring HIV due to testing positive for an STI were offered PrEP (Appendices B and
C). These results revealed a considerable gap between the CDC’s PrEP clinical practice
guidelines and actual clinical practice (CDC, 2014). The lack of standardized HIV risk screening
during API’s PrEP implementation is a contributing factor to this gap in practice. This is
significant because screening is the first step to prevention or treatment.
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Available Knowledge
Review of evidence: efficacy of PrEP for HIV prevention. A significant amount of
peer reviewed, placebo-controlled, randomized controlled trials (RCTs) demonstrate the
effectiveness of PrEP in preventing at-risk patients from acquiring HIV. The following evidence
from the World Health Organization (WHO) (2012) and the CDC (2014) suggest a strong impact
in protection rates against HIV when using PrEP. A literature review was completed to study the
methodology of PrEP trials and success rates, which summarized the evidence supporting PrEP.
The literature was retrieved from the provider resources folder located in API’s intranet, and
from searching the following key words on the CINAHL database: PrEP, pre-exposure
prophylaxis, HIV prevention. A critique of the reviewed literature was performed using the Johns
Hopkins Nursing Evidence Based Practice (JHNEBP) Research Evidence Appraisal instrument
(Appendix D).
The WHO (2012) conducted a meta-analysis of eight RCTs using TDF or TDF/FTC for
PrEP among the following populations and settings: a. heterosexual serodiscordant couples (in
which one partner is living with HIV) in Kenya and Uganda; b. heterosexual women and men in
Botswana; c. women at higher risk of contracting HIV in Kenya, South Africa and Tanzania; d.
men and transgender women who have sex with men from the landmark “iPrEX” study
conducted in Peru, Ecuador, Brazil, Thailand, South Africa, and the US. TDF/FTC’s
effectiveness in reducing HIV infection and its relationship with medication adherence were
analyzed. The result demonstrated 92% effectiveness in preventing HIV infection among
participants maintaining high medication adherence, as evidenced by their detectable serum
TDF/FTC level (WHO, 2012). The WHO study involved 14,951 participants. Results validated
that TDF/FTC for PrEP is 90-92% effective in preventing HIV infection in persons practicing
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high medication adherence. The CDC (2014) repeated this meta-analysis, also including a RCT
of 2,411 intravenous drug users (IDUs) in Bangkok, which produced similar results, thus
confirming PrEP’s effectiveness. The CDC then created the PrEP clinical practice guidelines
using this data.
The WHO (2015) later conducted another meta-analysis of 12 trials, supporting the
effectiveness of PrEP among serodiscordant couples, heterosexual men and women, men who
have sex with men (MSM), IDUs, and transgender women. These trials took place in Africa,
Asia, Europe, South America and the US. These results established that TDF/FTC for PrEP is
effective in reducing risk for HIV infection with high medication adherence, regardless of age,
gender, antiretroviral regimen, and mode of sexual transmission (WHO, 2015).
Additional information on PrEP recommendations. Additionally, the WHO (2015)
performed a qualitative literature review on administering PrEP to explore the cost-effectiveness,
equity, and acceptability of PrEP. The financial cost-effectiveness of PrEP varies depending on
the relative cost of PrEP versus HIV treatment. In terms of the demographic incidence of HIV,
preventing HIV transmission and keeping persons HIV-negative is invaluable to communities.
PrEP promotes equitable health outcomes of persons and their sexual partners, as well as access
to sexual health services during follow-up. Acceptability refers to how much the
recommendation of PrEP use is accepted by the patients who are affected by it and the healthcare
providers who can implement it (WHO, 2015). Widespread acceptability was reported across
multiple at-risk populations. Based on the results of this study, the WHO (2015) updated its
guidelines and now highly recommends starting PrEP not only for high-risk patients, but also for
patients with substantial risk for HIV infection per CDC guidelines (Appendix B). Substantial
risk for HIV infection is defined as meeting at least one of the following criteria in MSM,
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heterosexual, and IDU populations: HIV-positive sexual or injecting partner; recent bacterial
STI; high number of sex partners; history of inconsistent or no condom use; commercial sex
work; located in high-prevalence area or network; sharing injection equipment; and recent
intravenous drug treatment but currently injecting (CDC, 2014). Therefore, the WHO
recommends expanding PrEP uptake to a wider patient population.
Review of evidence: PrEP implemenation. Although significant evidence proves the
efficacy of PrEP in preventing HIV acquisition, a limited amount of studies demonstrating how
to best implement PrEP in the primary care setting exists (Scholl, 2015). The literature search for
this review of evidence was conducted using the CINAHL database by searching the following
key words: PrEP implementation, PrEP demonstration project, PrEP implementation model,
HIV risk screening, PrEP screening, primary care, and HIV prevention. The search yielded few
relevant articles about PrEP implementation, let alone in the primary care setting. No studies of
models for practicing PrEP implementation specifically in the primary care setting were
generated. A critique of the reviewed literature was also conducted using the JHNEBP Research
Evidence Appraisal instrument (Appendix E), confirming that most of the literature consisted of
qualitative studies identifying barriers to PrEP implementation, and implications for practice
(Scholl, 2015).
While no studies of PrEP implementation in the primary care setting were obtainable in
the literature search, studies performed in STI clinics demonstrate PrEP implementation models
targeting MSM. At a Rhode Island STD Clinic, PrEP implementation involved offering PrEP
education for every MSM patient presenting for STI testing, regardless of reported risk factors,
followed by a brief questionnaire assessing patient interest in PrEP, and a scheduled appointment
–for those who reported interest –with a provider for PrEP evaluation and initiation (Chan et al.,
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2016). Results across the PrEP implementation cascade reported that 60% expressed interest in
PrEP after receiving education; of whom 22% completed PrEP evaluation; and 81% of whom
actually initiated PrEP (Chan et al., 2016). Overall, only 10% of the targeted MSM initiated
PrEP. The results are primarily related to patients’ low HIV risk perception, indicating the
importance of emphasizing individual HIV risk factors to increase PrEP implementation.
Aiming to assess the feasibility and acceptability of implementing PrEP to MSM and
transgender women in the STI clinic and community health center setting, the US PrEP
demonstration project targeted these high-risk populations (Cohen et al., 2015). “The Demo
Project” implemented PrEP at STI clinics in San Francisco and Miami, and at a community
health center in Washington, D.C. At the San Francisco STI clinic, providers used the clinic’s
standardized HIV risk assessment, routinely administered to all MSM & transgender women, to
identify eligible patients for referral to participate in the study. MSM and transgender women
who requested PrEP were also referred for study participation –as “self-referrals”–if risk criteria
were met. In Miami, MSM and transgender women were informed about PrEP and the study. All
interested patients were referred to the PrEP team for prescreening prior to study participation.
While at the D.C. community health center, study staff directly approached MSM and
transgender women seeking HIV and STI screening to offer them the opportunity for
prescreening and participation in the study. Of the 557 participants enrolled, 60.5% completed
PrEP uptake. The participants’ demographic factors, behavioral risk characteristics, HIV risk
perception, and interest in PrEP were analyzed. Results show that PrEP uptake was high across
demographic factors and clinic sites. This indicated high levels of willingness to take PrEP if
patients accept its efficacy as an HIV prevention method, and if PrEP is provided at low or no
cost (Cohen et al., 2015). Although targeting only MSM and transgender women, the
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standardization of the prescreening intervention proved effective in recruiting participants and
producing high levels of PrEP uptake.
Most of the articles published on PrEP implementation models are qualitative studies that
identify barriers to increasing PrEP uptake (Appendix E). In a study of community FQHCs in
southeastern Florida, clinical staff perspectives on PrEP implementation were assessed
(Doblecki-Lewis & Jones 2016). The results were clear, that cultural stigma surrounding HIV
and sexual risk behaviors; concerns regarding documentation status, health insurance, and
financial cost; clinical staff knowledge of PrEP, and discomfort with discussing sexual history
and HIV risk screening contribute to the low implementation of PrEP despite serving high-risk
patient populations.
There is low PrEP implementation nationwide according to the narrative review
conducted by Silapaswan et al. (2016). Only a minority of at-risk persons who could benefit
from PrEP is taking it due to a limited number of healthcare practitioners trained to provide
PrEP. Addressing this barrier requires increased patient access to PrEP. Therefore, the authors
suggest that primary care practitioners should be the primary providers of PrEP because it is a
preventative health intervention for otherwise healthy individuals.
However, there are conflicting perspectives among healthcare providers regarding who is
best fit to provide PrEP and which healthcare setting is most appropriate for PrEP
implementation (Hoffman et al., 2016). For example, Hoover, Ham, Peters, Smith and Bernstein
(2016) suggest that PrEP is best implemented in STI clinics because of the shared sexual risk
behaviors related to acquiring HIV and other STIs, and persons infected with a bacterial STI are
more susceptible to HIV infection. Furthermore, STI clinics disproportionately provide services
for high-risk patient populations. Some primary care providers reported preference for HIV
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specialists, who are experts on antiretroviral therapy and HIV transmission, to serve as PrEP
providers (Hoffman et al., 2016). Meanwhile, some HIV specialists argue that HIV-negative
patients are not going to seek their services. Therefore, the wide net for health screenings cast in
the primary care setting supports that primary care providers are uniquely qualified for
prescribing PrEP (Hoffman et al., 2016). The lack of a unanimous stance on where PrEP belongs
in healthcare poses a significant barrier to its widespread dissemination. Further research using
implementation science is needed to determine the most effective setting for PrEP
implementation (Hoffman et al., 2016).
Although it is currently unclear which healthcare setting–STI clinics, community health
centers, HIV specialists, or primary care – is most appropriate for providing PrEP, the qualitative
studies in this review of evidence offer implications for practice to address barriers to PrEP
implementation. According to Doblecki-Lewis, and Jones (2016), Silapaswan et al. (2016), and
Hoffman et al. (2016), increasing provider knowledge of PrEP is the most common
recommendation across qualitative studies. Raifman, Flynn, and German (2016) identify that
provider knowledge is especially important as patient awareness of PrEP was found to be
unassociated with most healthcare contact. Training and guidelines are needed to support
provider discussion with patients about sexual history and PrEP. Furthermore, improved methods
for identifying at-risk patients who qualify for PrEP via routine sexual history/gender identity
questions are recommended to optimize PrEP implementation in the primary care setting
(Silapaswan et al., 2016).
Additional information on HIV risk screening in primary care. Because PrEP is a
preventative intervention that requires prescreening, it should be considered similar to other
preventative health services (Silapaswan et al., 2016). As with all routine screenings that are
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offered in primary care, such as AUDIT-C for alcohol dependence and PHQ-2 and -9 for
depression and suicide (Appendix A), HIV risk screening for PrEP implementation can also be
provided in this setting (Smith, Pals, Herbst, Shinde, & Carey, 2012).
In 2006, the CDC recommended the expansion of HIV screening to non-targeted (“optout”) routine HIV testing in all healthcare settings in the US (Haukoos et al., 2011). However,
non-targeted HIV testing was not widely adopted in clinical practice, especially in primary care,
because such large-scale screening is not cost-efficient (Haukoos et al., 2011). In 2007, the US
Preventative Services Task Force (USPSTF) recommended targeted (among high-risk
populations) HIV screening as the primary method of HIV testing (Haukoos et al., 2011). As a
compromise between the conflicting recommendations, the Denver HIV risk score, derived from
targeted HIV screening, was internally and externally validated by Haukoos et al. (2011). The
results of the study confirmed efficacious applicability of this HIV risk assessment tool across
healthcare settings, including non-targeted settings such as primary care.
The most current USPSTF recommendation for routine HIV screening in the primary care
setting states that one-time testing for HIV infection can begin at age 15 through age 65 with
repeat testing for those identified as at risk for HIV infection, engaged in risky behaviors, and
who live or receive medical care in a high-prevalence setting (US Preventative Services Task
Force, 2013). Because there is insufficient evidence to determine standard HIV testing intervals,
a reasonable approach is to screen high-risk groups at least annually, and at-risk groups every 3-5
years (USPSTF, 2013). However, there is no recommendation for HIV risk screening. HIV risk
screening in primary care can determine appropriate HIV testing intervals for individuals based
on identified HIV risk factors, as supported by the results of the Denver HIV risk score study
(Haukoos et al., 2011). Therefore, the Denver HIV risk score study supports the feasibility of
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increasing PrEP implementation in primary care through HIV risk screening. As preventative
health is one of the tenants of primary care, and the first step in prevention is screening, primary
care is the appropriate setting for routine HIV risk screening and PrEP implementation.
Smith et al. (2012) developed and validated a screening tool for identifying high-risk
MSM, for whom PrEP is appropriate, called the HIV Incidence Risk Index for MSM (HIRIMSM). The index included the following seven items: a. age; b. number of sex partners in the
past six months; c. number of times receptive anal intercourse performed in past six months; d.
number of HIV-positive sex partners; e. number of times insertive anal intercourse performed; f.
number of times methamphetamines used in the past six months; g. use of “poppers” in the past
six months? A cut-off score of 10 was found to be predictive of HIV acquisition with a
sensitivity of 84% and a specificity of 45%. Although the HIRI-MSM is a valid screening tool
targeting only MSM, the study of the index suggests widespread use for prioritizing at-risk
patients for PrEP (Smith et al., 2012). Therefore, expansion of an MSM-targeted screening tool
to other at-risk populations represents a model by which PrEP implementation in the primary
care setting can be increased.
Rationale
The core of this DNP project consisted of changing API’s PrEP implementation practice
by developing and implementing an HIV risk screening protocol by educating clinical staff,
employing an HIV PrEP screening tool, and integrating the change into routine clinical practice.
One theoretical framework used in the development of this project is the Diffusion of Innovation
Theory popularized by Everett Rogers (Kaminski, 2011). This theory represents the process that
occurs as people adopt a new practice. Over time, the innovative practice is diffused amongst the
population until a saturation point is reached, and the majority adopts the new practice as status
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quo. This theory is applicable to innovations in healthcare and health informatics (Angeles,
Dolovich, Kaczorowski & Thabane, 2014). The HIV risk screening protocol will diffuse among
the clinical staff at API, and has the potential to be adopted by other primary care clinics in San
Francisco if this DNP project’s model for PrEP implementation is disseminated.
The Awareness to Adherence Model, which states that provider compliance with clinical
practice guidelines is dependent upon the following steps: awareness, agreement, adoption, and
adherence (Freed, Pathman, Konrad, Freeman, & Clark, 1998). This model well describes the
way in which this project will bring awareness of the CDC (2014) PrEP clinical practice
guidelines through educating and training API providers and clinical staff on HIV risk
identification and following the HIV risk screening protocol. The API providers and clinical staff
will agree to follow the new HIV risk screening protocol after understanding its rationale and
benefits to their patient population. Adoption of the HIV risk screening protocol into routine
clinical practice should be effective due to API’s small size and few organizational barriers. The
author will be available to reinforce routine screening tool use to achieve adherence.
Specific Aims
The aim of this DNP project was to improve HIV prevention in a primary care setting
over a period of six months by increasing clinical staff identification of patients with substantial
risk for HIV, per CDC guidelines, through the implementation of a standardized HIV risk
screening protocol, as evidenced by increasing PrEP offer and evaluation for initiating TDF/FTC
for PrEP by 50% (Appendix F). The goal is to optimize HIV prevention at primary care clinics in
order to contribute to the Getting to Zero San Francisco initiative.
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Methods

Interventions
The primary intervention employed to change current practice and improve PrEP
implementation at API is the development of a standardized HIV risk screening protocol that
uses an HIV PrEP screening tool in the EHR. This will be accomplished by educating clinical
staff to routinely identify patients at risk for acquiring HIV who should be offered PrEP. The
HIV PrEP screening tool integrates the sexual history assessment with HIV risk screening to
streamline clinical practice. The following objectives describe the methods of the HIV risk
screening protocol:
1. Establish a standardized screening process: as patients are roomed, the MAs use the HIV
PrEP screening tool to assess for HIV risk and qualification for PrEP offer for each
establish new patient, STI testing, and annual physical exam patient encounter, and report
results to the providers.
2. Educate all clinical staff on routine HIV risk identification, per CDC criteria, using the
HIV PrEP screening tool and the new screening process.
3. Develop a standardized HIV PrEP screening tool and integrate it into the EHR (Appendix
G) to assist clinical staff in increasing identification of patients at substantial risk for HIV
acquisition, and subsequently increase PrEP offer and evaluation.
4. Develop clinical decision support tools in the EHR (Appendix H) to supplement the
optimization of PrEP implementation: a PrEP evaluation order set linked to ICD-10
diagnostic codes related to STI screening and treatment, and a PrEP evaluation progress
note template. The PrEP evaluation order set triggers providers to implement PrEP and
decreases EHR related burden for ordering evaluation and follow-up, and it includes a
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link to provider guidelines and patient education materials. The PrEP evaluation progress
note template streamlines and standardizes the documentation of PrEP evaluation.
5. Educate providers on accessing the PrEP clinical decision support tools.
6. Evaluate clinical staff comprehension with post-education tests (Appendix I).
7. Launch the HIV risk screening protocol for clinical practice at API.
8. Reinforce change by following up with clinical staff on HIV risk screening protocol
compliance –the routine utilization of the HIV PrEP screening tool per the established
screening process.
Gap analysis. Prior to initiating this DNP project, a gap analysis (Appendix J) of API’s
clinical practice of PrEP implementation was conducted through observation of clinical practice
and a baseline clinical data assessment (Appendix C). Based on observations of clinical practice,
a lack of standardization specifying the health screenings to be conducted for the type of patient
encounter was noted. Consequently, the sexual history assessment was performed inconsistently.
Furthermore, the sexual history assessment screen did not identify HIV risk despite the relevant
information it collected. Without appropriate clinical staff training to use sexual history
information to assess for HIV risk, the screen was ineffective for identifying at-risk patients who
should be offered PrEP. Additionally, differences in provider preference on which clinical staff
conducted health screenings (providers themselves or the MAs), and the high rate of clinical staff
turnover further contributed to inconsistencies in practice.
The baseline clinical data assessment was conducted by collecting and analyzing clinical
data from December 7, 2015 through April 8, 2016. Patient lists were generated from the
following data categories: STI treatment medications ordered, ICD-10 code Z11.3 (encounter for
screening for infections with a predominantly sexual mode of transmission), and STI lab tests
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ordered. The author performed individual patient chart reviews to identify those who qualified
for PrEP based on testing positive for an STI or sexual HIV risk (per CDC guidelines), and if
they were offered PrEP. The data analysis yielded the following gaps in identifying and offering
PrEP to patients with substantial risk for acquiring HIV per CDC guidelines. Of the patients with
a history of sexual HIV risk, 48% were offered PrEP (Appendix C). Of those who tested positive
for an STI, 35% were offered PrEP. Therefore, a significant gap exists between the number of atrisk patients who qualify for PrEP and the number of these patients who were actually offered
PrEP. According to this gap analysis, it was determined that API’s PrEP implementation
guidelines could benefit from a change in practice through this DNP project.
Gantt narrative. This DNP project timeline took place from March 2016 to February
2017 (Appendix K). In March 2016, the author visited API and spoke to Dr. Tri Do, the chief
medical officer (CMO), about the clinic’s needs. By the end of April 2016, the author selected
the DNP project topic after researching evidence-based literature on PrEP and conducting a gap
analysis of API’s PrEP implementation practice. June through September 2016 was spent
designing the HIV risk screening protocol –the implementation of an electronic screening tool
into clinical practice. The development of the HIV PrEP screening tool, the first critical
milestone, and the additional PrEP clinical decision support tools were completed in September
2016. The second milestone, clinical staff education was delayed by one month due to
scheduling conflicts, and was instead completed in October 2016. Subsequently, the HIV PrEP
screening protocol was launched on November 1, 2016, postponing the third milestone by one
month. The fourth and final milestone, evaluation of the intervention and its measurable
outcomes, started in January 2017 and was completed in February 2017.
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SWOT analysis. The following SWOT analysis describes API’s strengths, weaknesses,
opportunities, and threats that have the potential to affect the implementation of this DNP project
(Appendix L).
Strengths. API’s compassionate and culturally sensitive environment, its small
organizational size, FQHC status, and its specific patient population (LGBTQ and low-income
people of color) represent strengths. Because both the patient population and API staff share
similar backgrounds as LGBTQ community members and/or people of color, the culture at API
produces a trusting environment that is open to change for improvement. Since it is a small
organization, there is minimal bureaucratic pushback. Rather, the author receives support, such
as access to invaluable resources, from Dr. Blair Turner, the lead NP who supervised this DNP
project, and Dr. Do, the CMO/physician. FQHC status also contributes to API’s strengths
because federal funding reduces financial limitations to providing care. Furthermore, API’s
patients represent the at-risk population that qualifies for PrEP. Therefore, this DNP project is
appropriate and relevant. These strengths promote this DNP project’s capability to improve the
clinic’s PrEP implementation.
Weaknesses. The small size of API, high clinical staff turnover rate, and the outdated
EHR system represent weaknesses. Although API’s small organizational size is a strength
because it produces less resistance to change, its small size as a free-standing clinic also
represents a weakness. Since the clinic is not part of a larger health care system, it had few
standardized protocols and policies. During protocol development there were constant workflow
changes, resulting in difficulty establishing new protocol into routine. Additionally, the clinical
staff turnover rate is high because nurses and MAs are often volunteers or hired temporarily from
an agency, so new staff are constantly being trained. API’s EHR system represents another
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weakness because it is inefficient and has limited ability to capture clinical data. Difficulty
navigating the EHR was expected to pose problems in this DNP project during the baseline
assessment and evaluation. Therefore, project implementation was expected to face difficulties
with technology and adherence to change in practice.
Opportunities. The FQHC status API received in December 2015 creates the opportunity
to provide preventative care to more patients, and potentially meet the federally required EHR
meaningful use standards of promoting patient health outcomes (C. Ong-Flaherty, April 7, 2016).
FQHC status opens the clinic’s doors to more patients in the community, which represents an
opportunity to optimize HIV prevention efforts through PrEP implementation. Because the
patient population is at risk for acquiring HIV, this DNP project also has the opportunity to
produce potentially significant implications in public health by reducing HIV transmission and
improving patient outcomes in the community, which contribute to the Getting to Zero San
Francisco initiative. Patient health outcomes currently measured by EHR meaningful use
standards include scheduled immunizations, and flu and pneumonia vaccinations; and in acute
care for example, sepsis and heart failure (C. Ong-Flaherty, April 7, 2016). HIV prevention,
however, has not yet been established as a patient health outcome for meaningful use. If
established as a measurable outcome in the future, this DNP project can potentially help API
contribute to its meaningful use of the EHR by using an electronic HIV PrEP screening tool.
Threats. Patient refusal of PrEP due to cultural stigma, financial cost, and low HIV risk
perception represent threats. One of the barriers to PrEP uptake is cultural stigma. This cultural
stigma stems from pre-existing stigma around HIV, but specifically depicts patients taking PrEP
as “Truvada whores” (Calabrese & Underhill, 2015). Another barrier to PrEP uptake is financial
cost. While some health insurance plans, such as Medi-Cal, cover the entire cost of PrEP, others
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do not (T. Do, personal communication, May 9, 2016). Although API has a PrEP navigator to
connect patients with financial access to PrEP, the process of acquiring financial resources still
delays PrEP uptake. During this time waiting for financial coverage for PrEP, patients may
change their minds or not return to care. Low HIV risk perception is the main reason MSMs at a
Rhode Island STI clinic declined PrEP, representing an individual-level barrier to PrEP uptake
(Chan et al., 2016). For these reasons an identified at-risk patient may refuse PrEP evaluation,
and an eligible patient may refuse to initiate PrEP. Such threats may affect the PrEP
implementation cascade, and subsequently, this DNP project’s measurable outcomes.
Cost/benefit analysis. Because of API’s limited budget, this DNP project was created to
be without financial cost to API by utilizing available resources within the organization. API’s
full time equivalent (FTE) budget was not available to the author, so estimated costs are based on
equivalent San Francisco Department of Public Health job wages for each staff member’s hourly
wage. The estimated cost of this DNP project is $2,156.54, which consists of approximate FTE
employee hours spent by the following API staff members in project implementation: the CMO,
lead NP, volunteer NP, MAs, clinical data specialist, EHR system consultant, PrEP case
manager, clinical operations manager, and director of nursing (Appendix M). The author
absorbed the majority of this DNP project’s cost as an unpaid resource responsible for project
development and management. Therefore, project costs were absorbed into API’s FTE budget.
For other primary care clinics looking to adopt the HIV risk screening protocol, the cost
would primarily consist of FTE employee hours spent during clinical staff education, a project
manager to lead the implementation of the protocol, and potential information technology
assistance for integration into the EHR system. Based on Glassdoor’s database of salary reports,
the average hourly wage for a project manager consultant is approximately $42.52 (Glassdoor,
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2017). Including staff FTEs, as estimated above, and the cost to hire a project manager, the total
estimated cost for a primary care clinic to implement the HIV risk screening protocol is
$6,408.54 (Appendix M).
By preventing HIV infection, this DNP project produces a significant benefit of costavoidance of HIV management (Appendix M). HIV antiretroviral treatment costs approximately
$20,000 upwards per patient per year (CDC, 2015). The medication cost of PrEP is $13,000 per
patient per year. If all of API’s suspected at-risk patients (232) acquired HIV and required HIV
antiretroviral treatment, the estimated minimal cost of treatment is $4,640,000 per year. If started
on PrEP and HIV infection is prevented instead, the estimated cost is $3,016,000 per year. This
represents a potential cost avoidance of an estimated $1,624,000 per year.
By expanding PrEP implementation, this DNP project also produces a return on
investment (ROI) unique to the API clinic in the form of increased health insurance
reimbursements. Under its new FQHC status, API qualifies for Medi-Cal reimbursement at the
rate of $25 per patient per month for total cost of care (T. Do, personal communication, May 9,
2016). Based on the total estimated at-risk patients (232), assuming they are new to care and
Medi-Cal coverage, and are started on PrEP, API can potentially receive an estimated
reimbursement of $69,600 in one year (232 patients x $25 x 12 months per year) at this
reimbursement rate (Appendix N). This does not account for new Medi-Cal patients as API
continues to expand, nor future reimbursements from other health insurance plans as new
contracts are established. Thus, the estimated ROI is conservative and is promising for a new
FQHC clinic. It is important to clarify that initiating PrEP for established Medi-Cal patients does
not create additional reimbursement. However, PrEP care does require frequent follow-up, which
would keep patients in care, contributing to patient, and thus reimbursement, retention.
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Responsibility/communication plan. The planning involved in this DNP project
required extensive interdisciplinary responsibility and continuous communication (see Appendix
O for work breakdown and Appendix P for communication plan). Inter-professional
collaboration for this project occurred primarily between the author, Dr. Turner and clinical staff,
and the author’s DNP committee. Working directly with Dr. Turner, the author was responsible
for the development, management, implementation, and evaluation of the project. Dr. Turner and
Dr. Do provided assistance, serving as clinical experts of API’s patient population and HIV
prevention. As API’s lead NP and CMO, they provided authorization for this DNP project and
changes to clinical practice on site (see letter of support in Appendix Q). The clinical data
specialist assisted the author with retrieving data from the EHR, while the University of San
Francisco (USF) health informatics student intern provided assistance with data analysis, for the
baseline clinical data assessment. To assist the author with the cost/benefit analysis, the clinical
data specialist reported the approximate patient census for 2016. The API PrEP case manager,
whose role is to support PrEP patients and conduct outreach to introduce PrEP to the community,
provided invaluable advice for the appropriate approach to screening patients for HIV risk and
offering them PrEP. The clinical staff were educated and trained on the HIV risk screening
protocol. As the lead NP, Dr. Turner was considerably involved in this DNP project by providing
supervision, developing the HIV risk screening protocol with the author, and educating the other
providers.
Additionally, collaboration with the City Wide PrEP NP, who works for the San
Francisco Department of Public Health to assist primary care clinics in San Francisco with their
PrEP implementation needs through education and training, was planned for educating API’s
clinical staff. The following PrEP experts were also interviewed to research local PrEP
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implementation models during the design of the HIV risk screening protocol: the Gilead
Sciences assistant director of medical sciences for the west coast region, and local representative;
and the PrEP program managers at San Francisco City Clinic and Strut.
Study of the Intervention
After launching the HIV risk screening protocol, methods for assessing the effectiveness
of implementation and success of the HIV risk screening protocol were performed (Appendix R).
First, the clinical staff post-education test scores were evaluated. Not only did the tests assess the
clinical staff’s comprehension of the HIV risk screening protocol, HIV risk identification and
PrEP offer; they assessed the effectiveness of the educational training. Next, the author collected
three months of post-intervention clinical data from the EHR, starting from the launch date of the
HIV risk screening protocol on November 1, 2016 through February 1, 2017. Analysis of clinical
data from relevant patient encounters (STI testing, establish new patient, and annual physical
exam) evaluated staff compliance with the routine utilization of the HIV PrEP screening tool per
the established screening process. The author further analyzed the data for appropriate
completion of the PrEP implementation cascade to assess the effect of the HIV risk screening
protocol on improving API’s clinical practice of PrEP implementation.
Measures
Primary outcomes. The following primary outcomes were used to assess the
effectiveness of the HIV risk screening protocol based on improvement from baseline clinical
practice, as evidenced by an increase by 50% across the PrEP implementation cascade:
1. To increase PrEP offer to 72% of patients with sexual HIV risk, compared to the
baseline of 48% of patients with sexual HIV risk that were offered PrEP.
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2. To increase PrEP offer to 53% of patients tested positive for an STI, compared to the
baseline of 35% of patients tested positive for an STI that were offered PrEP.
3. To increase PrEP evaluation to 53% of patients offered PrEP, compared to the
baseline of 35% of patients offered PrEP that completed evaluation.
4. To increase PrEP uptake to 42% of patients evaluated and eligible for PrEP,
compared to the baseline of 28% of PrEP eligible patients that were prescribed
TDF/FTC.
Secondary outcomes. The following secondary outcomes were used to assess the
effectiveness of implementing the HIV risk screening protocol:
1. To achieve effective clinical staff educational training as evidenced by post-education
test scores of 80%.
2. To achieve adequate clinical staff compliance with using the HIV PrEP screening tool as
evidenced by a screening rate of 80% for each STI testing, establish new patient, and
annual physical exam patient encounter.
Maximizing internal and external validity. In order to maximize internal and external
validity, the percentage of identified at-risk patients offered PrEP, the percentage of patients
offered PrEP who completed PrEP evaluation, and the percentage of patients evaluated and
eligible for PrEP who completed PrEP uptake were calculated and analyzed. Comparing these
baseline and post-intervention percentages more accurately reflects the effect of the HIV risk
screening protocol on the PrEP implementation cascade. Because the HIV PrEP screening tool
asks similar questions as the internally validated Denver HIV risk score, it can be inferred that it
is also a valid tool for identifying HIV risk (Haukoos et al., 2011). Unlike the Denver HIV risk
score, the HIV PrEP screening tool does not produce a numerical score to detect HIV risk.
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Therefore, statistical testing is needed to confirm the validity of the HIV PrEP screening tool. As
the HIV PrEP screening tool asks questions specific to HIV risk criteria, it represents a reliable
tool for identifying patients at risk for acquiring HIV.
External validity of the HIV PrEP screening tool was maximized by incorporating HIV
risk and PrEP screening with sexual history assessment into one standardized screening tool. The
HIV PrEP screening tool is applicable to other primary care clinics in San Francisco because
sexual history assessments are conducted routinely in primary care, as should HIV risk screening
in San Francisco where HIV is endemic (SFDPH, 2016). Therefore, streamlining both processes
maximizes the HIV PrEP screening tool’s external validity. As previously mentioned, the HIV
PrEP screening tool asks similar questions as the Denver HIV risk score, which was also
externally validated, inferring the external validity of the screening tool (Haukoos et al., 2011).
Therefore, the HIV PrEP screening tool can be employed across patient populations and
healthcare settings in the US. However, statistical testing is needed to confirm the tool’s external
validity.
Instruments for assessment. The instruments used to assess the effectiveness of the HIV
risk screening protocol were API’s EHR system and Microsoft Excel (Appendix R). Because the
HIV PrEP screening tool was implemented and pertinent clinical data is documented into the
EHR system, the use of the EHR was required for the collection of clinical data analyzed for
evaluation. Microsoft Excel was used to perform the data analysis to assess intervention
effectiveness by calculating percentages and creating graphs to compare baseline and postintervention results (Appendix S).
Assuring validity of assessment instruments. Microsoft Excel is a valid instrument
because it is a data-analyzing software program that functions independently of API’s EHR
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system. Potential data entry error in Excel was addressed by re-checking electronically entered
totals multiple times for calculating pertinent values. However, human error in counting numbers
and entering data in Excel was still possible. The EHR has insufficient validity because of its
inconsistencies in retrieving clinical data. Meticulous clinical data collection was conducted to
assure data quality and accuracy. To ensure as complete a set of data as possible, multiple data
searches were performed, in line with the clinical data specialist’s instructions during the
baseline clinical data assessment, which generated patient lists from the following search
categories: STI testing, establish new patient and annual physical exam patient encounters, and
STI lab orders. From each list, the author performed individual patient chart reviews to identify
at-risk patients who qualify for PrEP, per CDC guidelines, and if PrEP offer, evaluation and
uptake were completed. To maintain consistency in data analysis method, duplications were
managed and deleted, and patients previously started on PrEP or living with HIV were excluded
from the sample, as performed in the baseline clinical data assessment.
Analysis
Only quantitative analytical methods were used in the evaluation of this DNP project, for
which quantified measurable outcomes were developed. Microsoft Excel, a long-standing
software program widely used in accounting, statistics, and sciences, was the software used to
analyze both the baseline and post-intervention clinical data. Through Excel, the results for each
measure were calculated as percentages, for which graphs were generated. Graphs comparing
baseline and post-intervention results revealed the effects of the HIV risk screening protocol
(Appendix S). While graphs displaying the clinical staff post-education test scores and HIV PrEP
screening tool compliance rates demonstrated the effectiveness of implementing the HIV risk
screening protocol.
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Ethical Considerations
Ethical considerations directly involved in the author’s DNP project implementation and
evaluation include patient privacy and potential conflict of interest. Patient privacy was protected
by strict adherence to the Health Insurance Portability and Accountability Act (HIPAA). While
this project was not research, per Institutional Review Board (IRB) guidelines, a waiver was filed
(Appendix F). The capture of clinical data from the EHR was conducted only at API within a
secure network. Patient names and personal information were excluded during the analysis of
clinical data for evaluation of the intervention. The author reports no personal or financial
conflicts of interest because her work is unpaid, and she is not affiliated with the pharmaceutical
company that manufactures TDF/FTC, public health departments, research or other HIV and
PrEP related organizations.
Implications for the ethical practice of PrEP implementation in primary care are
recognized by this DNP project. In accordance with the American Nurses Association Ethical
Standards and the Jesuit values of the University of San Francisco, the responsibilities of the
clinician and the healthcare site were examined. Providers must educate patients and weigh the
risks versus benefits of taking PrEP to practice beneficence and non-maleficence (Rowniak &
Portillo, 2013). To practice justice, providers must also serve as diligent patient advocates by
connecting disenfranchised, at-risk patients to social services necessary to access PrEP.
Furthermore, providers must fulfill their role as fiduciary stewards, and consider the financial
impact on the healthcare system and society while deciding whether to provide PrEP to a patient
(Atherton, Blodgett & Atherton, 2011) (Buck, 2016). Despite well-intentioned attempts,
providers must accept that their efforts to provide the best HIV prevention methods may still be
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blocked by forces outside of their control, such as patient autonomy and limited access to
necessary resources (Rowniak & Portillo, 2013).
Results
Primary Outcomes
Comparing baseline and post-intervention clinical data evaluated the effectiveness of the
HIV risk screening protocol (Appendix S). An increase by 50% from baseline was the
established target across the PrEP implementation cascade. The results demonstrated positive
effects:
1. At baseline, 48% of patients with sexual HIV risk were offered PrEP. After
implementation of the HIV risk screening protocol, 81% of at-risk patients were offered
PrEP, exceeding the target goal of 72%.
2. At baseline, only 35% of patients who tested positive for an STI were offered PrEP. At
post-intervention, 56% of these patients were offered PrEP, surpassing the target
percentage of 53%.
3. At baseline, 35% of patients who were offered PrEP completed PrEP evaluation. After
project implementation, 56% of these patients were evaluated for PrEP initiation, also
exceeding the target percentage of 53%.
4. At baseline, PrEP uptake for patients evaluated and eligible for PrEP was noted at 28%.
The post-intervention rate of 36% demonstrated an increase, but did not meet the target
goal of 42%.
Secondary Outcomes
The following secondary outcomes assessed the effectiveness of the implementation of
the HIV risk screening protocol (Appendix T).
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1. Adequate clinical staff comprehension and effective educational training as evidenced by
post-education test scores of 80%: Both of the two MAs and one of the two providers
completed their respective post-tests. The MAs’ test scores were 94% and 56%,
averaging 75%. The provider scored 75%.
2. Adequate clinical staff compliance with screening tool use as evidenced by a compliance
rate of 80% for each of the following patient encounters:
a. STI testing: 53% (n = 26)
b. Establish new patient: 74% (n = 62)
c. Annual physical exam: 100% (n = 1)
Discussion
Summary
Although the outcomes for PrEP offer and evaluation exceeded their respective target
percentages, the exact percentage targets for PrEP uptake and the secondary outcomes were not
met. Nonetheless, the aim to increase clinical staff identification of patients with substantial risk
for acquiring HIV, and subsequent increase in PrEP offer and evaluation for PrEP initiation were
still achieved. Project evaluation highlighted the importance of communication and reinforcing
change for effective improvement of clinical practice as targeted. Streamlining the sexual history
assessment and HIV risk screening into one standardized screening tool proved successful in
improving the clinical practice of PrEP implementation at API, as evidenced by increased
percentages across the PrEP implementation cascade. By sharing the HIV risk screening protocol
with the City Wide PrEP NP, the PrEP implementation model demonstrated by this DNP project
can be used by other primary care clinics in San Francisco. For clinics with limited EHR
capacities, the HIV PrEP screening tool can be converted into paper format. Ample clinical staff
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education and instruction on establishing a standardized screening process is essential for
effective optimization of PrEP implementation.
Interpretation and Limitations
The HIV risk screening protocol produced improvement across primary outcomes,
exceeding the target percentage of increase except for PrEP uptake (Appendix S). This is related
to pending health insurance coverage limiting PrEP uptake. If these patients had health insurance
coverage and received their prescriptions, 100% of those who cleared evaluation would have
completed PrEP uptake. Specifically measuring improvement in the gap in PrEP implementation
for patients who tested positive for an STI is an especially important clinical outcome. Although
PrEP offer increased by 60%, PrEP uptake for patients who tested positive for an STI did not
improve from baseline because patients declined PrEP initiation (Appendix U), indicating the
need for extensive and continuous patient discussions about PrEP. Often left unaddressed in
baseline clinical practice, testing positive for an STI indicates HIV risk. Previous studies have
shown that MSM in San Francisco who are diagnosed with rectal gonorrhea or chlamydia more
than once within two years are eight times as likely to acquire HIV; and in Florida, women with
syphilis were at the highest risk for subsequent diagnosis of HIV infection (Hoover et al., 2016).
As 56% of patients tested positive for an STI were offered PrEP, and the HIV PrEP screening
tool was used in 53% of STI testing patient encounters at post-intervention, reinforcement of
HIV risk screening protocol compliance is warranted to promote patient outcomes.
The results of the secondary outcomes also demonstrated unmet target percentages.
Because the average score for both MAs and the one provider who completed their posteducation tests was 75%, as opposed to the target score of 80% each, the effectiveness of the
clinical staff education was inadequate. This is related to limited time for clinical staff education,
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and a scheduling conflict that prevented the City Wide PrEP NP from providing education as
initially planned. A clinical staff compliance rate of 80% for screening tool use in STI testing
(53%) and establish new patient (74%) encounters was not met (Appendix T). Although the
annual physical exam patient encounter received a 100% clinical staff compliance rate, there was
only one documented case over the course of the post-intervention period (n = 1). Therefore this
result is unreliable. These unmet outcomes demonstrate the unsatisfactory effectiveness of
implementing the HIV risk screening protocol. Furthermore, API recently established additional
protocols to meet FQHC standards. Multiple changes in practice and the high rate of clinical staff
turnover, requiring frequent new employee training, resulted in clinical staff not following the
HIV risk screening protocol and the subsequent inadequate compliance rate for using the HIV
PrEP screening tool. Better clinical staff education, communication, and HIV risk screening
protocol reinforcement could have prevented the inadequate results of the secondary outcomes.
Additionally, the percentages of patients with substantial HIV risk at baseline (61%) and
post-intervention (38%) were calculated and compared to address potential changes to the patient
population and provide context for the results of the primary outcomes (Appendix V). The noted
difference in the percentage of patients with substantial HIV risk indicates a lower-risk patient
population for acquiring HIV at post-intervention. The decrease in at-risk patients consequently
affects the number of patients who qualify for PrEP offer, and subsequently evaluation and
uptake. The internal validity of this DNP project may have been compromised by this decrease in
the patient population’s HIV risk.
It is necessary to reiterate the limitations within API’s EHR system, namely the
inconsistencies in its capacity to retrieve clinical data. Despite the aforementioned measures to
assure internal validity, technological limitations may still have affected both baseline and post-
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intervention clinical data collection, and thus evaluation results. Although not all target outcomes
were met, the HIV risk screening protocol can still be a viable model for increasing PrEP
implementation in primary care, as supported by the studies of the Denver HIV risk score and
HIRI-MSM (Haukoos et al., 2011) (Smith et al., 2012).
Conclusions
The HIV risk screening protocol produced improvement in API’s clinical practice of
PrEP implementation by increasing PrEP offer, evaluation, and uptake. The minimal estimated
cost of the project, and significant cost avoidance and ROI, via health insurance reimbursement
estimates, demonstrate the HIV risk screening protocol’s cost-efficiency. Similar to other brief
screening tools used in primary care, the HIV PrEP screening tool for identifying HIV risk and
PrEP offer represents a useful clinical tool in the primary care setting, especially those in
endemic areas, for optimizing PrEP implementation and improving HIV prevention.
Implications for practice and future research were derived from the implementation of
this DNP project. Because STI infection represents one of the HIV risk criteria per CDC
guidelines, as patients with a history of STI infection have a higher susceptibility for acquiring
HIV, it is important to note the severity of the potential consequences of not capturing these
patients for PrEP offer (CDC, 2014) (Hoover et al., 2016). To effectively optimize PrEP
implementation in the primary care setting, as well as further improve clinical practice at API,
the relationship between STI testing/treatment and HIV risk screening for PrEP offer must be
emphasized and reinforced to clinical staff. Implications for future research include the
opportunity to evaluate the effectiveness of the HIV risk screening protocol if implemented at
other San Francisco primary care clinics; validate the HIV PrEP screening tool; and assess the
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HIV risk screening protocol’s impact on San Francisco’s HIV transmission rate and contribution
to Getting to Zero San Francisco.
Other Information
Funding
No internal or external funding was provided for any part in this DNP project, as its costs
were absorbed into API’s FTE budget. Therefore, funding played no major role in its design,
implementation, and interpretation.
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Appendix A
Definition of Terms

API: Asian and Pacific Islander Wellness Center
AUDIT-C: Alcohol Use Disorders Identification Test - Consumption
CDC: Centers for Disease Control and Prevention
CMO: Chief Medical Officer
DNP: Doctorate of Nursing Practice
EHR: Electronic Health Record
FQHC: Federally Qualified Health Center
FTE: Full Time Equivalent
HIRI-MSM: HIV Incidence Risk Index for Men who have Sex with Men
HIPAA: Health Insurance Portability and Accountability Act
HIV: Human Immunodeficiency Virus
IDU: Intravenous Drug User
IRB: Institutional Review Board
JHNEBP: Johns Hopkins Nursing Evidence Based Practice
LGBTQ: Lesbian, Gay, Bisexual, Transgender, Queer
MA: Medical Assistant
MSM: Men who have Sex with Men
NP: Nurse Practitioner
PHQ: Patient Health Questionnaire
PrEP: Pre-exposure Prophylaxis against HIV Infection
RCT: Randomized Controlled Trials
ROI: Return on Investment
STI: Sexually Transmitted Infection
TDF/FTC: Tenofovir Disoproxil Fumarate/Emtricitabine
UNAIDS: United Nations Program on HIV/AIDS
USF: University of San Francisco
US: United States
WHO: World Health Organization

HIV PREP

43
Appendix B
CDC Guidelines for Detecting Substantial Risk for Acquiring HIV

Men who have sex with men
HIV-positive sexual partner

Heterosexual men and
women
HIV-positive sexual partner

Recent bacterial STI

Recent bacterial STI

High number of sex partners

High number of sex partners

Injection drug users
HIV-positive injecting
partner
Sharing injection equipment

History of inconsistent or no
condom use

History of inconsistent or no
condom use

Commercial sex work

Commercial sex work

Recent drug treatment (but
currently injection)

In high-prevalence area or
network
*Note: Adapted from the Centers for Disease Control and Prevention. (2014). Preexposure prophylaxis for the prevention of HIV
infection in the United States: A clinical practice guideline. Retrieved from: https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf

HIV PREP

44
Appendix C
Baseline Clinical Data Assessment

Patients with sexual HIV risk who
were offered PrEP
60
50

48% of
patients
with
sexual HIV
risk

40
30
20
10
0
High sexual risk

PrEP offered

Patients tested positive for an STI
who were offered PrEP
16
14
12

35% of
patients
tested
positive
for STI

10
8
6
4
2
0
Positive for STI

Offered PrEP

* Note: Based on data from chart reviews of medical encounters for ordered STI testing from December 7, 2015 to April 8, 2016
(n =88).

Conceptual
Framework

Develop
ment of
clinical
practice
recomme
ndations

Develop
ment of
clinical
practice
guidelines

Citation

WHO (2012).
Guidance on PreExposure Oral
Prophylaxis (PrEP)
for Serodiscordant
Couples, Men and
Transgender Women
Who Have Sex with
Men at High Risk of
HIV:
Recommendations
for Use in the
Context of
Demonstration
Projects. World
Health Organization:
Geneva,
Switzerland.

Centers for Disease
Control and
Prevention (2014).
Preexposure
Prophylaxis for the
Prevention of HIV
Infection in the
United States: A
Clinical Practice
Guideline. US Public
Health Service.
Metaanalysis

Metaanalysis

Design/
Method

iPrEX Trial
n=2,499
US MSM Safety
Trial n=400
Hetero M/W
Partners PrEP
n=4,758
TDF2
N=1,219
Hetero W
FEM-PrEP
N=2,120
West African
Trial n=936
VOICE
n=3,0109
IVDU
BTS n=2,411

N = > 8,000
Trial 1: 6-county
iPrEx trial in
MSM/TGF.
Trial 2: women
at higher risk of
HIV Kenya,
South Africa,
Tanzania.
Trial 3:
heterosexual
men and women
in Botswana.
Trial 4: Partners
PrEP: HIV-1
serodiscordant
couples in Kenya
& Uganda.
Trial 5: The
VOICE trial of
Women in
Uganda, South
Africa, &
Zimbabwe.
MSM

Sample/
Setting

TDF & TDF/FTC
TDF

TDF/FTC
TDF

TDF & TDF/FTC
TDF/FTC

HIV Infection
rates,
medication
adherence.

Trial 1: HIV
infection rates,
measurable
serum drug
levels
indicating
medication
adherence.
Trial 2: HIV
infection rates.
Trial 3: HIV
infection rates.
Trial 4: Plasma
TDF levels,
indicating
medication
adherence, HIV
conversion
rates.
Trial 5: HIV
infection rates.

Trial 1: TDF/FTC in
MSM/TGF & HIV
acquisition.
Trial 2: daily PO
TDF/FTC in African
women at higher risk
of HIV.
Trial 3: daily PO
TDF/FTC in
heterosexual men and
women.
Trial 4: daily PO TDF
& daily PO TDF/FTC
among HIV-1
serodiscordant couples
in Kenya and Uganda.
Trial 5: Women in
Uganda, South Africa,
& Zimbabwe. Daily
PO TDF; daily PO
TDF/FTC; daily
topical TDF gel, vs.
placebos.
TDF/FTC
TDF

Measurement

Major Variables

Efficacy by med
adherence (blood
detection of drug)
iPrEx: 92%
Partners PrEP:
TDF: 86%
TDF/FTC: 90%
TDF2: TDF 85%
FEM-PrEP: NR
VOICE: NR
BTS: 74%

Efficacy Est (95% CI)
iPrEX: 44%
US MSM: NR
Partners PrEP
TDF: 67%
TDF/FTC 75%
TDF2:62%
FEM-PrEP: 6%
West African Trial: 65%
VOICE
TDF: 50%
TDF/FTC: 4%
BTS: 49%

N/A
Summary of
completed clinical
trials

Trial 1: 44% HIV
acquisition
reduction.
Trial 2:
inconclusive d/t
poor adherence.
Trial 3: reduced
risk of HIV
infection by 63%.
Trial 4: 67% overall
effectiveness w/
TDF; 75% overall
effectiveness w/
TDF/FTC. With
higher levels of
adherence: TDF
86% effective;
TDF/FTC 90%
effective.
Trial 5: unfinished.

Findings

Systematic reviews
of effectiveness,
safety, GRADE
profile analysis,
reviews of values &
preferences of
potential users &
consultations w/
key scientists,
implementers &
peer reviewers. The
Guidelines Steering
Group, the full
Guidelines
Development
Group, ^ the
External Review
Group conducted
the analysis.

Data Analysis

Strength of
Evidence:
Level 1
Quality A

Limitations:
Medication
adherence,
loss to
follow-up,
Heterosexua
l women
trials
stopped
early

Metaanalysis of
RCTs

Limitations:
Medication
adherence,
inconclusive
results from
2 RCTs.
Strength of
Evidence:
Level 1
Quality A

Metaanalysis of
RCTs

Appraisal
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Appendix D

PrEP Efficacy Evidence Tables using JHNEBP Research Evidence Appraisal

Conceptual
Framework

Comprehensi
ve revision
of 2013
guidelines
based on
new
evidence &
lessons from
implementati
on through
June 2015
via Clinical
Guideline
Development
Group.

Citation

WHO (2015).
Guideline on
When to Start
Antiretroviral
Therapy and
on PreExposure
Prophylaxis
for HIV.
World Health
Organization:
Switzerland.
External
peer
review

Qualitati
ve
Literature
Reviews

Systemati
c Review
& metaanalysis

Guideline
based on:

Design/
Method

Settings:
Trials
conducted in
India,
Indonesia,
Kenya, Peru,
Portugal,
Ukraine,
Zambia and
Zimbabwe.

14 RCTs,
3
observational
studies,
studies in
accordance
w/ PRISMA
reporting
guidelines

Sample/
Setting

Rationale &
supporting
evidence
Benefits vs
harm
Cost & costeffectiveness
Equity &
acceptability
Feasibility
Implementation
considerations
Research gaps.

Guideline
recommendatio
n based on the
following
criteria:

HIV infection

Major
Variables

Studies reviewed &
recommendations
developed using
GRADE method

HIV infection in
TDF vs
TDF/FTC vs
placebo.
PrEP
effectiveness in
high adherence
group (>70%
serum drug
detection) vs
moderate
adherence (4170% drug
detection) vs
low adherence
group (<40%
drug detection).
Drug resistance
to FTC in HIV
+ subjects (=
low).
Results:
PrEP trials
containing TDF =
effective in
reducing risk of
HIV infection,
regardless of age,
gender, regimen
(TDF VS
TDF/FTC), & mode
of infection.
Significant HIV
reduction in high
and moderate
adherence group; no
effect in low
adherence group.

Data Analysis

Measurement

New
recommendation
replaces the
previous WHO
recommendations
on PrEP and
enables the offer
of PrEP to be
considered for
people at
substantial risk of
acquiring HIV
rather than
limiting the
recommendation
to specific
populations,
including during
pregnancy.

Findings

Strength of
Evidence:
Level 1 & 3
Quality A

Limitations:
Medication
adherence, &
systematic
review used was
an unpublished
study

Qualitative
literature review

Meta-analysis
of RCTs

Appraisal
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PrEP Efficacy Evidence Tables using JHNEBP Research Evidence Appraisal (continued)

Conceptual
Frame
work

Analysis
of gaps
in PrEP
implementation
cascade.

Assessment of
PrEP
delivery
in
municipal
health
care
settings.

Citation

Chan, P. A., Glynn, T.
R., Oldenburg, C. E.,
Montgomery, M. C.,
Robinette, A. E.,
Almonte, A.,
… Nunn, A. S. (2016).
Implementation of
preexposure prophylaxis
for human
immunodeficiency virus
prevention among men
who have sex with men
at a New
England sexually
transmitted diseases
clinic. Sexually
Transmitted Diseases,
43(11),
417-422.

Cohen, S. E.,
Vittinghoff, E., Bacon,
O., Doblecki-Lewis, S.,
Postle, B. S., Feaster, D.
J.,…Liu, A. Y. (2015).
High interest in
preexposure prophylaxis
among men who have
sex with men at risk for
HIV infection: baseline
data from the US PrEP
demonstration project.
Acquired Immune
Deficiency Syndrome,
68(4), 439-448.
Participant
enrollment,
HIV risk
behaviors,
PrEP
awareness,
interest in
PrEP.

PrEP
eligibility
criteria.
Screening
participants
for PrEP.
Enrollment
of
participants
in study.
PrEP uptake.
Sociodemographics, & sexual
& drug use
behaviors.
HIV risk
perception.
Prep

N= 557
STD
clinics in
San
Francisco &
Miami:
MSM &
transgender
women.
Community
health
center in
Washing
-ton, DC:
MSM &
transgender
women.

Prospective, longitudinal openlabel cohort study.
Method: MSM and transgender
women were targeted and
prescreened for referral to
participate in the study, then
screened for PrEP eligibility,
followed by completion of a
detailed intervieweradministered questionnaire on
demographics and sexual and
drug-use behaviors. Those
who cleared PrEP screening
were “enrolled” for PrEP
initiation and received
TDF/FTC at no cost for 48
weeks.
awareness.

Number of
participants
included in the
following steps
of the PrEP
implementation cascade:
Educated about
PrEP;
interested in
PrEP; received
follow-up
contact;
scheduled
provider
appointment;
attended
provider
appointment;
initiated PrEP
(received Rx).

Measurement

Lack of
interest.
Lack of
patient
acceptabilit
y of PrEP.

Major
Variables

New
England
Sexually
Transmitted
Diseases
Clinic
N=234
MSM.

Sample/
Setting

Demonstration project
Method: Every MSM seeking
STD related services were
offered education on PrEP. If
agreeable, they were provided
PrEP education. Their interest
in PrEP was then assessed. For
those interested in PrEP,
follow-up was conducted to
schedule an appointment with
a provider for evaluation to
initiate PrEP. For those who
kept their provider
appointments and met PrEP
criteria, they were prescribed
PrEP. Brief questionnaire
assessed reasons behind
patients’ lack of interest or
refusal to initiate PrEP.

Design/
Method

Data

Multivariable
Poisson
regression model
assessed
predict-ors
of enrollment.
Multivariable
descriptive
statistical
analyses
of participant
characteristics.

Bivariate
and multivariable
logistic
regression models
to examine
predict-ors
of PrEP
initiation.

Analysis

Participants who were selfreferred, those with previous
PrEP awareness, and those
reporting > 1 episode of anal
sex with an HIV-positive
partner in the last 12 months
were more likely to enroll.
98% of enrolled participants
were MSM. At baseline,
63.5% of MSM reported
condomless receptive anal sex
in the previous 3 months.
Overall, interest in PrEP is
high among a diverse
population of at-risk MSM
when offered at STD or
community health clinics.

Educated about PrEP: 234
Interested in PrEP: 56%
Received follow-up scontact:
53% of those interested
Scheduled provider
appointment: 51% of those
who followed up
Attended provider
appointment: 77% of those
who schduled an appointment
Initiated PrEP (rceived Rx):
95% of those who attended the
appointment
Reasons for lack of interest in
PrEP: 37% low HIV risk
perception; 10% more time to
consider; 7% concern about
side effects; 3% financial
barriers
Reason for not scheduling an
appointment: low HIV risk
perception.

Findings

Strength of
Evidence:
Level 3
Quality B

Limitations
: no control
group

Qualitative
study

Strength of
Evidence:
Level 3
Quality C

Limitations
: low HIV
risk
perception,
lack of
provider
knowledge
about PrEP.
No control
group.

Nonexperimental study

Appraisal
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Appendix E

PrEP Implementation Evidence Tables using JHNEBP Research Evidence Appraisal

Practice
recommendations

Silapaswan, A.,
Krakower, K., &
Mayer, K. H.
(2016). Preexposure
prophylaxis: a
narrative review
of provider
behavior and
interventions to
increase PrEP
implementation
in primary care.
Journal of
General Internal
Medicine, 32(2),
192-198.
Method: Previous
qualitative studies
of provider
behavior, attitudes,
and intentions
toward PrEP
provision were
summarized to
develop practice
recommendations
to optimize PrEP in
the primary care
setting.

Narrative review
Multiple
studies. Exact
number nor
specified.

N= 22 clinic
staff
4 community
health centers
in
southeastern
Florida, 3 of
which are
FQHCs.

Qualitative study of
focus group
discussion themes

Focus group
study to explore
the feasibility,
acceptability,
and uptake of
PrEP in an
endemic area.

Doblecki-Lewis,
S., & Jones, D.
(2016).
Community
federally
qualified health
centers as homes
for HIV
preexposure
prophylaxis:
perspectives
from south
Florida. Journal
of the
International
Association of
Providers of
AIDS Care,
15(6), 522-528.
Method: 6-7 staff
members from each
clinic were
interviewed. Brief
demographic
background
information was
collected, and focus
group discussions
were moderated by
a study investigator
using a semistructured guide.

Sample/
Setting

Design/
Method

Conceptual
Framework

Citation

Provider
behavior,
attitudes, and
intentions
toward PrEP
provision.

Staff perceptions
of: PrEP
implementation
practice; PrEP
interest among
patients; PrEP
acceptability
among patients
and providers;
concerns and
barriers to PrEP.

Major
Variables

Barriers to PrEP
“real world”
effectiveness.
Potential
unintended
clinical
consequences.
Purview Paradox.

Themes derived
from focus group
discussions.

Measurement

Metasynthesis.
Limitations:
Methods not
discussed.
Unknown
sample size.
Low internal
validity.
Strength of
Evidence:
Level 3
Quality C

Barriers to PrEP:
PrEP efficacy &
medication adherence;
provider logistics;
potential unintended
clinical consequences
(ARV drug resistance
PrEP drug toxicity);
behavioral
disinhibition & STIs.
Purview Paradox: HIV
specialists have higher
PrEP awareness than
PCPs. Practice
recommendations:
Increase provider
education & training
on PrEP. Optimize
medication adherence
and PrEP acceptability
through community
engagement. Improve
identification of
appropriate patients
for PrEP.

Summarizes
findings from
previous studies,
otherwise not
specified.

Qualitative
study.
Limitations:
potential
bias from
arbitrary
theme
development
by study
team
members
compromise
s validity.
Strength of
evidence:
Level 3
Quality C

Themes surrounding
PrEP: need for
increased provider
knowledge about
PrEP; perception of
low PrEP demand
among patients; cost
and risk assessment
as perceived barriers
to PrEP; concerns
about adherence and
risk compensation.

Audio recordings of
focus group
discussions were
transcribed.
Transcripts
uploaded to
Dedoose version
5.0.11 for analysis.
Open coding of
transcripts further
developed themes.
Coded transcripts
were reviewed by
study team
members, resolving
differences by
discussion and
mutual agreement,
for accuracy.

Appraisal

Findings

Data Analysis
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PrEP Implementation Evidence Tables using JHNEBP Research Evidence Appraisal (continued)

Conceptual
Framework

Hoffman, S., Guidry, J.
A., Collier, K. L.,
Mantell, J. E., BoccherLattimore, D.,
Kaighobadi, F.,
& Sandfort, T. G.
(2016). A clinical home
for preexposure
prophylaxis: diverse
health care providers’
perspectives on the
“Purview Paradox.”
Journal of the
International
Association of Providers
of AIDS Care, 15(1), 5965.

Multidisciplinary
interviewing

Hoover, K. W., Ham, D. Models of
C., Peters, P. J., Smith,
Practice
D. K., & Bernstein, K.
T. (2016). Human
immunodeficiency virus
prevention with
preexposure prophylaxis
in sexually transmitted
disease clinics. Sexually
Transmitted Diseases,
43(5), 277-282.

Citation

Qualitative study of
interview data.
Method: practicing
clinicians who provide
care for MSM, IDUs, &
high-risk heterosexual
women were recruited
& provided education
on PrEP. Extensive
interviewing (1-1.5 hrs)
of each participant was
conducted by study
coinvestigators or
project director about
the following topics:
PrEP knowledge;
prescribing guidelines;
prior experience
prescribing PrEP; skills
needed to implement
PrEP in one’s practice
& anticipated
challenges; perceptions
of peers’ opinions of
PrEP; intentions to
implement PrEP, & to
whom; anticipated
training needs;
preferences for
continuing education
modalities.

Method: summary of
evidence regarding
PrEP efficacy and
higher risk of HIV
infection related to
STD infection. Models
of PrEP
implementation in
STD clinics are
described.

Commentary

Design/
Method

N = 30
providers:
24 MDs,
4 NPs, 2
PAs.
Setting:
greater
New
York
metropolitan
area.

Sample:
n/a
Setting:
STD
clinics

Sample/
Setting

Major

Purview
Paradox:
who
should
provide
PrEP?
(HIV
specialists
vs. PCPs).

PrEP
uptake in
the US
has been
low.

Variables

Interviews
were
transcribed
and coded
for global
topics.

STD
infection as
objective
biological
markers for
HIV risk.

Measurement

Final codes
were
applied to
documents
using a
computerized
qualitative
program
(Atlas.ti),
after which
coding
reports
were
produced
for each
global
code.
Coding
grids were
derived
from the
reports to
identify
participant
characteristics.

n/a

Data
Analysis

A diverse group of participants
favored PrEP implementation in
non-HIV specialty settings, but were
divided on whether they thought
primary care providers could achieve
all the skills and services espoused
with PrEP provision.

High-risk patient populations
disproportionately seek care at STD
clinics, and STD infections increase
the susceptibility for HIV
acquisition, therefore STD clinics
are the optimal setting for PrEP
implementation.
Recommendations:
Model 1: PrEP services provided
directly at STD clinic.
Model 2: STD clinic captures PrEP
eligible patient and provides referral
to a PrEP provider in the
community.

Findings

Qualitative study.
Limitations:
potential bias since
interview content
was coded by study
team members,
which compromises
internal validity.
Strength of
Evidence:
Level 3
Quality C

Meta-synthesis.
Limitations: no trials
studied. Method not
discussed. No
evaluation of
effectiveness of
models for practice.
Strength of
Evidence:
Level 3
Quality C

Appraisal
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PrEP Implementation Evidence Tables using JHNEBP Research Evidence Appraisal (continued)

Dissemination of
PrEP
awareness

Raifman, J. R.,
Flynn, C., &
German, D.
(2017).
Healthcare
provider contact
and preexposure
prophylaxis in
Baltimore men
who have sex
with men.
American
Journal of
Preventative
Medicine, 52(1),
55-63.

Haukoos, J. S., HIV risk
Lyons, M. S.,
screening
Lindsell, C. J.,
tool
Hopkins, E.,
Bender, B.,
Rotham, R. E.,
… Byyny, R. L.
(2011).
Derivation and
validation of the
Denver human
immunodeficien
cy virus (HIV)
risk score for
targeted HIV
screening.
American
Journal of
Epidemiology,
175(8), 838846.

Conceptual
Framework

Citation

N = 401
MSM
Setting:
2014
Baltimore
NHBS
data.

Derivation
sample:
92,635, of
which 504
HIV-pos.
Setting:
Denver
Metro
Health
Clinic
(STD
clinic).
Validation
sample:
22,983
Setting:
University
of
Cincinnati
Medical
Center
ER.

Method: data
from the 2014
MSM wave of
National HIV
Behavioral
Surveillance
(NHBS) in
Baltimore were
collected and
analyzed for
exposures to
healthcare versus
community
based
organization
(CBO) contacts
and PrEP
awareness.
Screening tool
development;
internal &
external
validation.
Method: Denver
HIV risk score
derived from
analysis of
prospectively
collected data
from routine
assessment patient
information
required for HIV
testing, producing
HIV risk
prediction model.
Internal validity
established, then
externally tested
at a different
healthcare site in
another state.

Sample/
Setting

Qualitative data
analysis

Design/
Method

Major

Predictive value of
variables; predictive
ability of Denver HIV
risk score model;
predictive HIV
prevalence vs observed
HIV prevalence.

Demographic
characteristics,
symptoms,
STI hx, sexual
hx, specific
sexual
practices &
condom use,
gender of
sexual
contacts,
previous HIV
testing hx,
other risk
factors for
HIV
transmission.
Confirmed
HIV infection
served as the
outcome/
dependent

variable.

Exposures to healthcare
vs CBO contacts:
1. Seeing a healthcare
provider in the past 12
mo; 2.Having a usual
source of care; 3.Being
out to a healthcare
provider; 4.Receiving
HIV testing from
healthcare provider;
5.Getting tested for HIV;
6.Getting tested for STI;
7.Testing positive for an
STI; 8.Participating in
individual HIV
prevention counseling;
9.Participating in group
HIV prevention
counseling; 10.Receiving
free condoms from an
HIV CBO; 11. Receiving
free condoms from an
LGBT CBO.

Measurement

PrEP
awareness
related to
healthcare vs
CBO
contacts.

Variables

Visiting a healthcare
provider in the past 12 mo,
receiving an HIV test from a
provider, and having an STI
test in the past 12 mo were
not significantly associated
with PrEP awareness.
PrEP awareness was
positively associated with
being out to a healthcare
provider (p<0.001); being
tested for HIV (p=0.023); &
receiving condoms from an
HIV/AIDS CBO (p=0.001).
HIV testing was significantly
associated w/ most forms of
healthcare contact.
Healthcare providers are
providing HIV testing to
MSM, but not PrEP.

Final Denver HIV risk score
included predictive variables:
age, gender, race/ethnicity,
sex w/ a male, vaginal
intercourse, receptive anal
intercourse, IDU, & past
HIV testing.
HIV prevalence for the
following scores:
<20: 0.31%
20-29: 0.41%
30-39: 0.99%
40-49: 1.59%
50 and up: 3.59% (95% CI
each).
Denver HIV risk score
accurately categorizes
patients into groups with
increasing probabilities of
HIV infection.

Derivation: Denver HIV risk
model development: multivariable logistic regression,
bivariate statistical testing,
Akaike’s Information
Criterion for global test of
good fit, statistical analysis
of predictive ability of
variables. Internal validity:
10-fold cross- validation &
calibration by graphically
comparing predicted HIV
prevalence w/ observed HIV
prevalence. External validity:
data managed w/ Microsoft
Access. Statistical analyses:
SAS, version 9.2; Stata,
version 10.1; SPSS, version
18. Markov chain Monte
Carlo approach - to promote
validity of results.
Bootstrapping approach to
estimate 95% CI for
regression coefficients of
final model.

Findings

Stata, version 12, was
used to conduct analyses:
associations between
healthcare contacts and
PrEP awareness were
estimated via logistic
regression models
controlling for age, race
and education, and
clustering by venue.
Additional comparative
analyses between PrEP
and other HIV prevention
intervention were
conducted with HIV
testing as an outcome.
Healthcare provider and
CBO contact regarding
HIV testing in the past
year was evaluated.
Lastly, statistical analysis
was conducted.

Data Analysis

Derivation:
Meta-synthesis
External
validation:
Quasiexperimental
study.
Limitations:
qualitative data
within variables
r/t patient
answers. High
quality data
analysis:
multiple
software &
approaches
assured internal
& external
validity.
Strength of
Evidence:
Levels 3 & 2
Quality A

Metasynthesis
Limitations:
no
quantitative
data as it was
a qualitative
study, but
otherwise
thoroughly
assured
internal
validity.
Strength of
Evidence:
Level 3
Quality A
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PrEP Implementation Evidence Tables using JHNEBP Research Evidence Appraisal (continued)

Conceptual
Framework

Smith, D. K.,
Brief HIV risk
Pals, S. L.,
screening tool
Herbst, J. H.,
Shinde, S., &
Carey, J. W.
(2012).
Development of
a clinical
screening index
predictive of
incident HIV
infection among
men who have
sex with men in
the United States.
Journal of
Acquired
Immune
Deficiency
Syndromes,
60(4), 421-427.

Citation

VAXGEN
004 RCT data
set N = 4,643
HIVuninfected
MSM from
57 US sites
Project
EXPLORE
RCT data set
N = 4,295
HIVuninfected
MSM from 6
US cities.

Prospective data
analysis for
screening tool
development,
followed by
internal validation.
Method: Analysis
of data from 2
existing large data
sets from HIV
prevention trials
that enrolled HIVuninfected MSM in
the US, collected
risk behavior data
and HIV test results
every 6 mo, & that
had at least 100
HIV
seroconversions
over the course of
the trial. MSM in
active and control
arms of the trial
data sets were
included.
Questionnaires used
in both data set
trials were
reviewed to select
screening
questions. Point
scores for the index
were developed.
The final screening
tool model was
developed: HIV
Incidence Risk
Index for MSM
(HIRI-MSM).

Sample/
Setting

Design/
Method

Residence in one
of the top 10
metropolitan
statistical areas
in the US ranked
by HIV
prevalence.

Any selfreported STI.

Non-injection
substance use
(poppers,
amphetamines,
hallucinogens,
cocaine, or
sildenafil).

In past 6 months:
Sexual behavior
(# sex partners, #
times of
unprotected
receptive anal
sex; # times of
unprotected
insertive anal
sex, each by
reported HIV
status of
partner).

Age

Major
Variables

Predictive
ability of
variables

Measurement

Final logistic
regression model
for HIRI-MSM
included:
Age;
During past 6 mo:
Total # of male sex
partners; total # of
HIV-positive male
sex partners;
number of times of
unprotected
receptive anal sex
w/ a male partner
of any HIV status;
Number of times of
insertive anal sex
w/ an HIV-positive
male partner; use
of poppers; use of
amphetamines.

Generalized estimating
equations were used to fit
logistic regression
models to adjust for overtime correlation in
variables.
Statistical analysis of
predictive ability of each
variable.
Bootstrap and backward
elimination procedure
were used to select
variables for the final
model, which included
only those with P<0.05
statistical significance.
Multiplication of
regression coefficients
for each by 10 and
rounded to the nearest
integer was conducted to
develop point scores for
the index. Point values
for all variables in the
model were summed to
establish a high-risk
MSM index score.
Different score cut-offs
established by computing
sensitivity, specificity,
and area under ROC
curve.
Index scores range
from 0-47
Score of 10 & up
has sensitivity of
84% & specificity
of 45%, levels
appropriate for a
screening tool.

Area under ROC
curve: 0.74

Findings

Data Analysis

Quality A

Strength of
Evidence:
Level 3

Limitations: no
trial to assess
implementation
of HIRI-MSM.
Lacks external
validity

Meta-synthesis

Appraisal
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PrEP Implementation Evidence Tables using JHNEBP Research Evidence Appraisal (continued)

HIV PREP

52
Appendix F
Statement of Determination
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Statement of Determination (continued)
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Statement of Determination (continued)
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Appendix G
HIV PrEP Screening Tool Implemented into the EHR

*Note: Highlighted answers indicate HIV risk and PrEP offer/discussion of PrEP
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Appendix H
Clinical Support Tools Implemented into the EHR

PrEP order set linked to STI-related ICD-10 diagnoses:
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Clinical Support Tools Implemented into the EHR (continued)

PrEP evaluation progress note template:
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Appendix I
Clinical Staff Post-Education Tests

Medical Assistant Test:
HIV Risk Screening Protocol
1. Which of the following are signs that indicate eligibility for PrEP? (Highlight all that
apply)
□ Recent STI diagnosed in the past 6 months
□ Current STI diagnosis
□ 80% condom use for vaginal and/or anal sexual intercourse
□ Illicit drug use
□ Multiple sexual partners of known HIV -negative status
□ Multiple sexual partners with 100% condom use
□ Monogamous relationship with HIV-positive sexual partner
□ Injection drug use without equipment sharing and uses clean needles only
□ History of syphilis from 10 years ago
□ Monogamous relationship with HIV-negative partner
□ HIV-negative injecting partner
□ Exchanges sex for rent
□ Transgender woman who is asexual
□ HIV-positive injecting partner
2. True or False: At the end of the sexual health assessment, always ask the patient if they
have heard of PrEP. (Highlight answer)
a. True
b. False
3. After conducting the sexual health assessment, what do you do next? (Highlight answer)
a. Report results of the patient’s sexual health assessment to the provider at huddle.
b. State whether or not the patient is eligible for PrEP and ask the provider to discuss
PrEP with the patient.
c. Both a & b
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Clinical Staff Post-Education Tests (continued)

Provider Test Part 1:
HIV Risk Screening Protocol
1. Which of the following are signs that indicate eligibility for PrEP? (Highlight all that
apply)
□ Recent STI diagnosed in the past 6 months
□ Current STI diagnosis
□ 80% condom use for vaginal and/or anal sexual intercourse
□ Injected drug use
□ Multiple sexual partners of known HIV -negative status
□ Multiple sexual partners with 100% condom use
□ Monogamous relationship with HIV-positive sexual partner
□ Injection drug use without equipment sharing and uses clean needles only
□ History of syphilis from 10 years ago
□ Monogamous relationship with HIV-negative partner
□ HIV-negative injecting partner
□ Exchanges sex for rent
□ Transgender woman who denies sexual activity in the last 12 months
□ HIV-positive injecting partner
2. True or False: At the end of the sexual health assessment, always ask the patient if they
have heard of PrEP, unless they are already on PrEP. (Highlight answer)
a. True
b. False
3. After a patient’s STI test result comes back positive, what do you do next? (Highlight
answer)
a. Treat the STI
b. Discuss PrEP (and document)
c. Both a & b
4. What is the purpose of integrating the sexual health assessment with PrEP eligibility
screening? (Highlight answer)
a. To make using ECW more complicated to use.
b. To identify PrEP eligible patients.
c. To ultimately increase PrEP uptake among patients at risk for acquiring HIV
infection.
d. b & c

HIV PREP

60
Clinical Staff Post-Education Tests (continued)

Provider Test Part 2:
Clinical Decision Support Tool: Triggered PrEP Order Set
1. True or False: When sexual health risk related ICD-10 diagnoses codes are entered, the
PrEP evaluation order set will be triggered. (Highlight answer)
a. True
b. False
2. How do you access the triggered PrEP evaluation order set? (Highlight answer)
a. Do nothing, it will automatically appear.
b. Click on the “stop sign” button that will turn red on the upper right corner of the
ECW screen.
c. Enter each order for PrEP evaluation individually.
3. Where is the “stop sign” button for accessing triggered order sets located? (Highlight
answer)
a. It will pop up in the center of the ECW screen.
b. It will turn green in the left corner of the ECW screen.
c. It will turn red in the right corner of the ECW screen.
4. What is the purpose of the triggered PrEP order set? (Highlight answer)
a. To make ordering everything required for PrEP evaluation easier and more
streamlined.
b. To make ECW more complicated to use.
c. To ultimately increase PrEP uptake among patients at risk for acquiring HIV
infection.
d. Both a & c
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Appendix J
Gap Analysis

Current
Situation

Inconsistent
clinical practice
of HIV risk
screening.

Future
Situation/
Goal

Standardized
process for HIV
risk screening
and PrEP
implementation.

No standardized
practice for PrEP 100% of patients
implementation. at risk for
acquiring HIV
are identified
and offered PrEP
for HIV
prevention.

Gaps

48% of patients
with history of
sexual HIV risk
are offered
PrEP.
35% of patients
tested positive
for an STI are
offered PrEP.
*Note: See baseline
clinical data
assessment in
Appendix C

Factors

Remedies

Lack of
standardization
of clinical
practice that
specifies routine
health
screenings to be
conducted for
the type patient
encounter.

Standardized
screening tool
for sexual
history
assessment and
HIV risk.

Provider
preference on
which clinical
staff performs
routine health
screenings:
providers vs.
MAs.
High rate of
clinical staff
turnover.

Standardized
HIV risk
screening
protocol that
utilizes
screening tool
for specified
patient
encounters.
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Appendix K
Gantt Chart
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Appendix L
SWOT Analysis
Strengths

•

Weaknesses

Compassionate and culturally

•

No standardized protocols

sensitive environment

•

Many changes to clinic workflow

•

Small organizational size

•

Outdated EHR

•

FQHC status

•

High rate of clinical staff turnover

•

Patient population represents at-risk
population eligible for PrEP

•

Chief medical officer and lead
provider support
Opportunities

Threats

•

At-risk patient population

•

Patient refusal of PrEP

•

FQHC status: more primary care

•

Cultural stigma

patients

•

Financial cost of PrEP

Screening tool implementation using

•

Low HIV risk perception

•

EHR system potentially contributes to
meaningful use for possible future
HIV prevention standard
•

Improve patient outcomes in HIV
prevention

•

Implications for public health safety:
Getting to Zero San Francisco
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Appendix M
DNP Project Cost Summary

Costs Absorbed into the Asian and Pacific Islander Wellness Center FTE Budget
API staff member
Estimated hourly
Number of hours
Subtotal cost (FTE)
wage (FTE)1
spent on project
CMO/Physican
$93.48
2
$280.44
Lead NP
$71.61
20
$1,432.20
Volunteer Nurse
$0
0.33
$0
Practitioner
(20 min)
Medical Assistant (4)
$31.66
0.33
$41.79
(20 min)
Director of Nursing
$67.00
0.33
$22.11
(20 min)
PrEP Case Manager
$30.00
1
$30.00
EHR System
$55.00
2
$110.00
Consultant
Clinical Data
$30
8
$240.00
Specialist
DNP Author/Project
$0
163
$0
Manager
Estimated cost of DNP project
$2,156.54
Cost for Primary Care Clinics to Implement HIV Risk Screening Protocol
Staff leader for
Estimated hourly
Number of hours
Subtotal cost (FTE)
implementation
wage of project
anticipated to be
manager (FTE)2
spent on project
implementation
Project Manager
$42.52
100
$4,252.00
Estimated cost of for primary care clinics
$6,408.54
Clinical staff costs ($2,156.54) + project manager
1API

staff wage estimates from equivalent City and County of San Francisco public health job listings. Retrieved from
http://www.jobaps.com/SF/
2Project manager wage estimate based on average salary for project manager consultant in San Francisco reported by Glassdoor.
Retrieved from https://www.glassdoor.com/Salaries/project-management-consultant-salary-SRCH_KO0,29.htm
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DNP Project Cost Summary (continued)

Cost-Avoidance Estimate
HIV management costs
$20,000+ per patient per year1
Estimated HIV management costs for the
Estimated cost of $320,040,000 spent in 2015
reported 16,002 people living with HIV in San
if every person was on HIV antiretroviral
Francisco at the end of 20152
treatment
Estimated total cost of HIV management if all
A minimum of $4,640,000 per year
232 patients suspected at-risk acquired HIV
infection3
Cost of PrEP
$13,000 per patient per year1
Estimated total cost of PrEP for all 232
$3,016,000 per year
3
patients suspected at risk for HIV acquisition
Estimated cost avoidance by starting all 232
A minimum of $1,624,000 per year
suspected at-risk patients on PrEP3
1Centers

for Disease Control and Prevention. (2015). HIV cost effectiveness. Retrieved from
http://www.cdc.gov/hiv/programresources/guidance/costeffectiveness/index.html
2San Francisco Department of Public Health. (2015). HIV Semi-annual surveillance seport. Retrieved from
https://www.sfdph.org/dph/files/reports/RptsHIVAIDS/HIV-SemiAnnualReport122015.pdf
3
Estimated number of at-risk patients based on approximate 2016 unique patient census of 381 as reported by API’s clinical data
specialist (C. Ong-Flaherty, personal communication, April 5, 2017).
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Appendix N
Budget Return on Investment Plan

Medi-Cal reimbursement rate to API: $25 per patient per month per year1
Percentage of patients at risk for HIV
acquisition
Approximate total number of patients
at end of 2016
Estimated number of patients suspected at
risk for acquiring HIV

61%2
3813
232

Medi-Cal reimbursement estimate if all at-risk patients are new to care and Medi-Cal coverage
are started on PrEP:
232 patients x $25 x 12 months per year= $69,600 in one year

*Note: Estimate based on assumption that the 232 at-risk patients are new to care and Medi-Cal coverage. Established Medi-Cal
patients who initiate PrEP would not produce additional reimbursement cash flow, but for PrEP follow-up would keep them in
care, contributing to patient and reimbursement retention. Minimal reimbursement estimate. Does not include other health
insurance plan reimbursement rates.
1 Per API’s CMO. (T. Do, personal communication, May 9, 2016).
2 Based on baseline clinical data assessment.
3 Based on approximate 2016 unique patient census as reported by API’s clinical data specialist (C. Ong-Flaherty, personal
communication, April 5, 2017).
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Appendix O
Work Breakdown Structure by Person

Stakeholder
Dr. Tri Do
Chief medical officer
API physician
DNP co-chairs: Drs.
Chenit Ong-Flaherty and
Prabjot Sandhu
DNP committee: Dr.
Stefan Rowniak

Project Role
Authorization

Item/Event
Change in practice
approval

Special Instructions
Review and approve project and
screening tool intervention

Authorization, guidance,
critique and assessment of
implementation and
evaluation.

DNP project
approval

Assist and support with
development and approval of
DNP project.

Dr. Blair Turner
Lead NP

Supervision and guidance
of project

Change in practice:
HIV risk screening
protocol

Provide supervision, assistance,
and support for development of
project.

DNP author/Project
manager: Cara Nalagan

Project developer,
manager, and evaluator

Change in practice:
HIV risk screening
protocol

EHR system consultant,
clinical data specialist and
USF health informatics
student intern

EHR system navigation

Baseline clinical
data assessment,
electronic
screening tool

PrEP case manager

Intervention design

Change in practice

Gilead Sciences assistant
director of medical
sciences for the west
coast region, and local
representative
San Francisco City Clinic
and Strut PrEP program
managers
City Wide PrEP NP

Intervention design

Change in practice

Develop, implement, and
evaluate HIV risk screening
protocol to optimize PrEP
implementation.
Assist with using EHR system to
conduct baseline clinical data
assessment, and with
development of screening tool
into the EHR.
Provide input for designing
appropriate HIV risk screening
protocol.
Provide input for designing
appropriate HIV risk screening
protocol.

Intervention design

Change in practice

Intervention design,
clinical staff education,
and potential
dissemination

Change in practice

Clinic providers and staff
(MD, NPs, RNs, MAs,
clinic operations manager,
director of nursing)

Intervention recipients

Change in practice

Provide input for designing
appropriate HIV risk screening
protocol.
Provide input for designing
appropriate HIV risk screening
protocol, assist with clinical staff
education, and potentially
disseminate protocol to other
primary care clinics in SF.
Learn and follow HIV risk
screening protocol to increase
identification of patients at risk
for acquiring HIV and increase
provider offer of PrEP.
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Appendix P
Communication Plan by Item/Event

Item/Event

Purpose

Audience

Brainstorm

Develop
appropriate HIV
risk screening
protocol

EHR system
navigation

Baseline clinical
data assessment,
Development of
HIV PrEP
screening tool in
the EHR system

Dr. Turner,
DNP
committee,
Gilead Sciences
support
representatives,
San Francisco
City Clinic and
Strut PrEP
managers, City
Wide PrEP NP,
PrEP case
manager, and
the author
Dr. Turner and
the author

Implementation
of HIV risk
screening
protocol

Increase
identification of
patients at risk
for acquiring
HIV and
increase
provider offer of
PrEP.
Evaluate
effectiveness of
intervention

Evaluation

Date/
Frequency
May 31, 2016 to
September 6,
2016

Who is
Responsible
The author and
Dr. Turner

Authority &
Release
Dr. Turner (lead
NP) and Dr. Do
(CMO)

August 7, 2016
to September 6,
2016

Clinical data
specialist, EHR
system
consultant, Dr.
Turner, and the
author

Dr. Turner (lead
NP) and Dr. Do
(CMO)

Clinical staff &
providers

October 16,
2016 to
February 1,
2017

The author and
Dr. Turner

Dr. Turner (lead
NP) and Dr. Do
(CMO)

Clinical staff
and providers

January 9, 2017
to February 5,
2017

The author

Dr. Turner (lead
NP) and Dr. Do
(CMO)
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Appendix Q
Authorization

HIV PREP

70
Appendix R
Evaluation Plan
Deadline

Evaluation

October 23, 2016

Clinical staff comprehension
of HIV risk identification and
screening tool use
Clinical staff compliance rate
of 80% for routine screening
tool use

February 1, 2017

February 1, 2017

February 5, 2017

Method

Screening tool post-education
test with a passing score of
80%
Retrieve clinical data from
the EHR system and use
Microsoft Excel to calculate
the percentage of screening
tool use per STI testing,
establish new patient, and
annual physical exam patient
encounter
An increase by 50% in PrEP
As evidenced by the data
offer for patients with sexual captured by the screening tool
HIV risk, and for patients
and by individual chart
tested positive for an STI
reviews in the EHR and
compared to baseline
analyzed in Microsoft Excel
by calculating percentages
An increase by 50% in PrEP
and generating graphs,
evaluation for patients offered repeated in a similar method
PrEP, and in PrEP uptake for
used in the baseline clinical
eligible patients compared to
data assessment
baseline
HIV risk screening protocol
Complete evaluations and
summarize results using
Microsoft Excel to calculate
percentages and generate
graphs to compare baseline
and post-intervention results
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Appendix S
Results of Primary Outcomes

1. Baseline: 48% of patients identified with sexual HIV risk were offered PrEP.
Target: 72%
Post-intervention: 81% of patients identified with sexual HIV risk were offered PrEP.

Percentage of patients with sexual HIV risk who
were offered PrEP
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

PrEP Offered

Baseline

Post Intervention

2. Baseline: 35% of patients tested positive for an STI were offered PrEP.
Target: 53%
Post-intervention: 56% of patients tested positive for an STI were offered PrEP.

Percentage of patients tested positive for an STI
who were offered PrEP
60%
50%
40%
30%

PrEP Offer s/p STI Dx

20%
10%
0%
Baseline

Post Intervention
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Results of Primary Outcomes (continued)

3. Baseline: 35% of patients offered PrEP completed PrEP evaluation.
Target: 53%
Post-intervention: 56% of patients offered PrEP completed PrEP evaluation.

Percentage of PreP evaluation completed for
patients offered PrEP
60%
50%
40%
30%

PreP Evaluation
Completed

20%
10%
0%
Baseline

Post Intervention

4. Baseline: 28% of patients evaluated as eligible for PrEP completed PrEP uptake.
Target: 42%
Post-intervention: 36% of PrEP eligible patients were prescribed TDF/FTC for PrEP.

Percentage of PrEP prescribed to patients
evaluated as eligible for PrEP
40%
35%
30%
25%
20%

PrEP Prescribed

15%
10%
5%
0%
Baseline

Post Intervention
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Appendix T
Results of Secondary Outcomes

1. Clinical staff comprehension of HIV risk identification and screening tool use as
evidenced by a post-test score of at least 80%: MA1 scored 94%; MA2 scored 56%; and
Provider 1 scored 75%

Clinical Staff Test Scores
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
MA 1

MA 2

Provider 1

2. Clinical staff compliance rate for routine HIV PrEP screening tool use of 80% for each
STI testing, establish new patient, and annual physical exam patient encounter: 53%,
74%, and 100%, respectively

Utilization of HIV PrEP Screening Tool Compliance
120%
100%
80%
60%
40%

n = 26

n = 62

STI testing

Est. New Patient

n=1

20%
0%
Annual Physical Exam
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Appendix U

Comparison of PrEP Implementation Cascade for Patients Tested Positive for an STI at Baseline
and Post-Intervention

PrEP Implementation after STI Diagnosis
60.0%

50.0%

40.0%

30.0%

20.0%

10.0%

0.0%
STI Dx among All Pts

STI Dx among High Risk Pts
Baseline

PrEP offered among STIpositive Pts

PrEP started among STIpostive Pts

Post-Intervention

*Note: Only one out of five post-intervention patients agreed to initiate PrEP after evaluation; the rest declined PrEP uptake.
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Appendix V

Comparison of Patient Population HIV Risk at Baseline and Post-Intervention

Percentage of At-Risk Patients Among Sample
70%
60%
50%
40%
Identified as At-Risk

30%
20%
10%
0%
Baseline

Post Intervention

*Baseline patient sample over a four-month period of data collection n= 88. Post-Intervention patient sample over a
three-month period of data collection n=95.

